Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating Expenses:
Research and development	$ 4,125	$ 3,029	$ 13,530	$ 6,346
General and administrative	2,843	2,321	8,671	7,353
Total operating expenses	6,968	5,350	22,201	13,699
Operating loss	(6,968)	(5,350)	(22,201)	(13,699)
Other income (expense):
Investment income, net	41	25	111	118
Other expense, net	0	0	(90)	0
Total other income (expense)	41	25	21	118
Net loss before benefit from income taxes and noncontrolling interests	(6,927)	(5,325)	(22,180)	(13,581)
Benefit from income taxes	0	0	(1,508)	(10,872)
Net loss	(6,927)	(5,325)	(20,672)	(2,709)
Less - net income attributable to noncontrolling interests	0	2	0	10
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (6,927)	$ (5,327)	$ (20,672)	$ (2,719)
Basic and diluted loss per share
Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)	$ (0.12)	$ (0.29)	$ (0.38)	$ (0.19)
Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)	$ (0.12)	$ (0.29)	$ (0.38)	$ (0.19)
Weighted average common shares outstanding
Basic shares	59,614	18,597	53,811	14,116
Diluted shares	59,614	18,597	53,811	14,116